Eroje M. Ahmed
A HIF-independent, CD133-mediated mechanism of cisplatin resistance in glioblastoma cells
Ahmed, Eroje M.; Bandopadhyay, Gagori; Coyle, Beth; Grabowska, Anna M.
Anna M. Grabowska
Glioblastoma Multiforme (GBM) is the commonest brain tumour in adults. A population of cells, known as cancer stem cells (CSCs), is thought to mediate chemo/radiotherapy resistance. CD133 is a cell surface marker to identify and isolate CSCs. However, its functional significance and the relevant microenvironment in which to study CD133 remain unknown. We examined the influence of hypoxia on CD133 expression and the potential functional significance of CD133 in glioblastoma chemoresistance.
Gene expression was analysed by qRT-PCR. siRNA technique was used to downregulate genes and confirmed by flow cytometry. IC50 values was evaluated with the Alamar blue assay.
CD133 expression was upregulated in hypoxia in 2D and 3D models. There was increased resistance to chemotherapeutics, cisplatin, temozolomide and etoposide, in cells cultured in hypoxia compared to normoxia. siRNA knockdown of either HIF1a or HIF2a resulted in reduced CD133 mRNA expression with HIF2a having a more prolonged effect on CD133 expression. HIF2a downregulation sensitized GBM cells to cisplatin to a greater extent than HIF1a but CD133 knockdown had a much more marked effect on cisplatin sensitisation than knockdown of either of the HIFs suggesting a HIF-independent mechanism of cisplatin resistance mediated via CD133. The same mechanism was not involved in temozolomide resistance since downregulation of HIF1a but not HIF2a or CD133 sensitized GBM cells to temozolomide.
Knowledge of the mechanisms involved in the novel hypoxia-induced CD133-mediated resistance to cisplatin observed might lead to identification of new strategies that enable more effective use of current therapeutic agents.
|Journal Article Type||Article|
|Publication Date||Jun 30, 2018|
|Peer Reviewed||Peer Reviewed|
|APA6 Citation||Ahmed, E. M., Bandopadhyay, G., Coyle, B., & Grabowska, A. M. (2018). A HIF-independent, CD133-mediated mechanism of cisplatin resistance in glioblastoma cells. Cellular Oncology, 41(3), https://doi.org/10.1007/s13402-018-0374-8|
|Keywords||Hypoxia; Cisplatin; Temozolomide; Chemoresistance; CD133; HIFs|
|Copyright Statement||Copyright information regarding this work can be found at the following address: http://creativecommons.org/licenses/by/4.0|
Copyright information regarding this work can be found at the following address: http://creativecommons.org/licenses/by/4.0
You might also like
Immunostaining for DNA modifications: computational analysis of confocal images
Long-term exposure to irinotecan reduces cell migration in glioma cells.
Overcoming multiple drug resistance mechanisms in medulloblastoma